WHO Coca Leaf Review Leaves the Leaf Beside Cocaine

The World Health Organization has declined to recommend that the coca leaf be classified separately from cocaine, the refined alkaloid extracted from it. The outcome of the WHO coca leaf review was reported by IDPC, which noted that the leaf therefore remains listed in the same international company as heroin and fentanyl.

The review was carried out by the WHO’s Expert Committee on Drug Dependence, known as the ECDD. IDPC reports that it was responding to a request initiated by Bolivia in 2023 and later supported by Colombia, asking for the leaf’s status under the UN 1961 Single Convention on Narcotic Drugs to be reconsidered.

Reaction from La Paz was blunt. According to IDPC, former Bolivian Vice-President David Choquehuanca called the decision an “egregious mistake” and said that six decades of UN prohibition had violated Indigenous sovereignty and the right to use the leaf for food, healing and ritual.

What Bolivia and Colombia actually asked for

The request was not a proposal to legalize cocaine. It asked the international system to stop treating a chewed, brewed and ground plant as though it were the concentrated drug made from it.

• The coca leaf contains 1 percent or less of the cocaine alkaloid, per the figure cited by IDPC.
• The 1961 Single Convention sets the rules for 138 different substances and has been ratified by 186 countries.
• Bolivia and Colombia argued the leaf does not belong beside substances that are readily abused or easily converted into illicit drugs.
• The ECDD did not recommend separating the leaf’s classification from cocaine’s.

IDPC’s account does not state what procedural step comes next, or whether any further review has been scheduled. We are not going to guess at one. What is clear is that the recommendation the two governments sought did not arrive.

Why the 1 percent figure is the whole argument

Concentration is not a technicality here. It is the difference between an agricultural product and a pharmaceutical one, and it is the reason the comparison to heroin and fentanyl reads as a category error rather than a cautious judgment.

A leaf carrying a fraction of a percent of an alkaloid behaves in the body nothing like an isolated, purified dose of that alkaloid. That is not an exotic claim about coca; it is how plants and their extracts generally work. Coffee cherries are not pharmaceutical caffeine, and willow bark is not aspirin.

This is also why we keep returning to the peer-reviewed literature rather than the press cycle — our coverage of the HerbalGram coca issue looked at what happens when the leaf is examined as a plant, on the record, by scientists.

The sovereignty question the scheduling debate keeps avoiding

The strongest case for the status quo is worth stating honestly: coca is the feedstock for the global cocaine trade, and any loosening of its international status could be read as a signal to that trade. Countries that have spent decades and enormous sums on interdiction have a real institutional stake in not sending that signal.

But that argument answers a question nobody asked. Bolivia’s request concerned the leaf, not the alkaloid. Cocaine’s controlled status was never on the table, and declining to distinguish the two does not make the leaf more dangerous — it only keeps millions of traditional users classified alongside people who never touched a plant.

Choquehuanca’s framing, as reported by IDPC, puts that in terms of Indigenous sovereignty: a use pattern that long predates the Convention has been governed for six decades by an instrument written without it.

Why this matters

Our reading is that this is a setback, not a settlement. The ECDD is an advisory body, and its failure to recommend a change resolves nothing about the underlying science, which is exactly where the case for the leaf has always been strongest.

For American readers, the practical effect is limited and indirect. IDPC’s report does not address US scheduling or agency positions, and we will not extrapolate a domestic consequence the source does not describe. What the decision does affect is the argument’s altitude: descheduling advocates hoped to win the point at the level of global health expertise, and that route stayed shut for now.

The people with the most at stake are the growers and traditional users in Bolivia, Colombia and Peru, whose everyday practice remains formally abnormal under a treaty that 186 countries have ratified. Anyone who cares about drug policy being evidence-led rather than inherited should treat that as unfinished business — and should notice how rarely the 1 percent figure appears in coverage that lumps leaf and drug together.

Frequently Asked Questions

What did the WHO decide about the coca leaf?

The World Health Organization's Expert Committee on Drug Dependence declined to recommend that the coca leaf's international classification be separated from that of cocaine. As a result, the leaf remains listed alongside substances such as heroin and fentanyl under the international system. The committee's decision was a refusal to recommend change rather than a new restriction.

Who asked the WHO to review the coca leaf's status?

Bolivia initiated the request in 2023, and Colombia later backed it. The two governments asked for the coca leaf's status under the UN 1961 Single Convention on Narcotic Drugs to be reconsidered, arguing the leaf does not belong beside substances that are easily abused or readily converted into illicit drugs.

How much cocaine is actually in a coca leaf?

The coca leaf contains 1 percent or less of the cocaine alkaloid. That is a very different thing from cocaine, which is the isolated and purified alkaloid extracted and processed from large quantities of leaf. The distinction between the plant and the drug is central to the case Bolivia and Colombia brought to the WHO.

What is the 1961 Single Convention on Narcotic Drugs?

It is the United Nations treaty that sets the international control rules for 138 different substances, and it has been ratified by 186 countries. The coca leaf is among the substances it covers. Bolivia's 2023 request sought to have the leaf's placement within that treaty reconsidered.

Does the WHO decision change the law in the United States?

No US legal change has been reported in connection with the WHO Expert Committee on Drug Dependence declining to recommend a new classification for the coca leaf. The committee is an advisory body within the international system, and its recommendations are not themselves national law. Anyone asking about US scheduling should look to US authorities rather than assume a domestic effect.

What happens next after the WHO refused to reclassify coca?

No further procedural step or new review date has been stated. What is established is that the recommendation Bolivia and Colombia sought did not come from the WHO's Expert Committee on Drug Dependence. Whether the two governments pursue another route has not been announced.

Why do Indigenous leaders in Bolivia object to the coca leaf's UN status?

Former Bolivian Vice-President David Choquehuanca described the WHO's refusal as an egregious mistake and said six decades of UN prohibition on the coca leaf had violated Indigenous sovereignty. He pointed to the leaf's long-standing use for nutrition, healing and ritual, practices that predate the 1961 treaty governing them.